Topiramate Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 470

Clinical Trials

Numerous clinical trials, spanning Early Phase 1 through Phase 4, investigate topiramate across diverse neurological, metabolic, and psychiatric conditions, including migraine, obesity, Tourette syndrome, postoperative pain, and HIV-1 infection. Sponsored by prominent academic institutions such as Stanford University and the University of Minnesota, as well as pharmaceutical organizations like Eli Lilly and Janssen-Cilag, the research landscape reflects broad clinical utility. Across these initiatives, trial statuses encompass completed evaluations, active recruitment, and planned future studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07655440	NOT_YET_RECRUITING	Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine	Stanford University	2026-07	PHASE4
NCT07790913	NOT_YET_RECRUITING	Acute Lymphoblastic Leukemia in Remission; Hodgkin Lymphoma in Remission; Non-Hodgkin Lymphoma in Remission; Cancer Survivorship	St. Jude Children's Research Hospital	2026-09	PHASE2
NCT06972056	RECRUITING	Migraine	Mayo Clinic	2025-07-09	PHASE4
NCT07384624	NOT_YET_RECRUITING	HIV (Human Immunodeficiency Virus); HIV -1 Infection	Erasmus Medical Center	2026-04	PHASE1; PHASE2
NCT05209984	WITHDRAWN	Overweight; Obesity	Eurofarma Laboratorios S.A.	2026-04	PHASE3
NCT07213466	RECRUITING	Bipolar I Disorder; Bipolar II Disorder; Schizo Affective Disorder; Obesity; Weight Loss; GLP - 1	Mayo Clinic	2026-01-19	PHASE4
NCT05582837	RECRUITING	Ménière	University of California, Irvine	2022-08-01	PHASE4
NCT03307863	SUSPENDED	Contraception; Drug Interactions	University of Sao Paulo	2017-11-01	PHASE4
NCT05975580	RECRUITING	Obesity	University of California, Irvine	2023-08-29	PHASE4
NCT06854614	ACTIVE_NOT_RECRUITING	Obesity	The Cleveland Clinic	2025-03-01	PHASE4
NCT07707544	ACTIVE_NOT_RECRUITING	Idiopathic Intracranial Hypertension	Sohag University	2026-06-01
NCT06799169	ACTIVE_NOT_RECRUITING	Tinnitus	University of California, Irvine	2025-06-01	PHASE4
NCT06499116	NOT_YET_RECRUITING	Migraine	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	2024-10	PHASE4
NCT02808533	ACTIVE_NOT_RECRUITING	Schizophrenia, Schizoaffective Disorder	Centre for Addiction and Mental Health	2016-05
NCT05834062	WITHDRAWN	Obesity, Adolescent	University of Minnesota	2023-10-17	PHASE2
NCT04298203	COMPLETED	Obesity	University of Minnesota	2021-08-04	PHASE2
NCT06347497	COMPLETED	Migraine	Kafrelsheikh University	2024-04-01	PHASE3
NCT06299891	RECRUITING	Hypothalamic Obesity; Hypothalamic Tumor; Craniopharyngioma	Seattle Children's Hospital	2025-03-01	PHASE2
NCT04613024	WITHDRAWN	Weight Loss; Pain, Postoperative	Stanford University	2025-07-01	EARLY_PHASE1
NCT04881799	ACTIVE_NOT_RECRUITING	Pediatric Obesity	University of Minnesota	2022-07-07	EARLY_PHASE1
NCT03667846	RECRUITING	Post Traumatic Stress Disorder; Alcohol Use Disorder	NYU Langone Health	2019-10-10	PHASE2
NCT05403229	UNKNOWN	Sudden Deafness; Sudden Sensorineural Hearing Loss	Chang Gung Memorial Hospital	2022-10-17	PHASE2
NCT05748483	COMPLETED	Migraine	AbbVie	2023-10-07	PHASE3
NCT06282783	UNKNOWN	HIV-1-infection; Hiv; HIV Infections; HIV I Infection	Erasmus Medical Center	2024-09	PHASE1; PHASE2
NCT04007393	COMPLETED	Adolescent Obesity	University of Minnesota	2019-11-21	PHASE2
NCT06243692	UNKNOWN	Migraine Disorders	Kafrelsheikh University	2024-02-01	PHASE3
NCT05579249	COMPLETED	Obesity	Novo Nordisk A/S	2023-01-19	PHASE4
NCT04621929	COMPLETED	Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes	University of Florida	2021-03-31	PHASE2
NCT05958160	UNKNOWN	Epileptic Spasms, Failed Hormonal Therapy	Lady Hardinge Medical College	2023-07-20	PHASE2; PHASE3
NCT04986631	COMPLETED	Obesity, Childhood	University of Minnesota	2022-04-04	EARLY_PHASE1
NCT06282783	Not yet recruiting	HIV-1-infection\|Hiv\|HIV Infections\|HIV I Infection	Erasmus Medical Center	2024-09	Phase 1\|Phase 2
NCT04581603	TERMINATED	Alcohol Use Disorder With Insomnia	VA Office of Research and Development	2022-06-15	PHASE4
NCT03689114	COMPLETED	Epilepsies, Partial	Mario Negri Institute for Pharmacological Research	2021-05-10	PHASE4
NCT04721873	RECRUITING	Colitis, Ulcerative; Obesity	University of California, San Diego	2020-12-18	PHASE2
NCT06248931	COMPLETED	Migraine Disorders	Kafrelsheikh University	2022-05-01	PHASE3
NCT06089356	UNKNOWN	Migraine	Tanta University	2023-01-01	PHASE4
NCT04404439	COMPLETED	Tinnitus, Subjective; Tinnitus	University of California, Irvine	2019-09-26	PHASE4
NCT05975580	Recruiting	Obesity	University of California Irvine\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2023-08-29	Phase 4
NCT05663749	COMPLETED	Metabolic Syndrome; Schizophrenia	All India Institute of Medical Sciences, Bhubaneswar	2022-09-20	PHASE4
NCT04613024	Not yet recruiting	Weight Loss\|Pain Postoperative	Stanford University	2023-07-01	Early Phase 1
NCT05516251	UNKNOWN	Migraine, Classic	Tongji Hospital	2021-10-01
NCT05759845	UNKNOWN	Migraine	Dr. Reaz Mahmud	2022-08-22	PHASE4
NCT01950520	COMPLETED	Healthy Volunteers	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2014-02-07	PHASE2
NCT03176953	COMPLETED	PTSD and Alcohol Use Disorder	VA Office of Research and Development	2017-11-01	PHASE2; PHASE3
NCT03603080	TERMINATED	Obesity	Hartford Hospital	2019-03-01	PHASE4
NCT04531176	TERMINATED	Type 2 Diabetes; Obesity	The Cleveland Clinic	2020-09-01	PHASE4
NCT04408586	COMPLETED	Obesity	Mayo Clinic	2020-06-03	PHASE4
NCT04572217	WITHDRAWN	Pediatric Obesity	Janey Pratt	2022-06-01	PHASE2
NCT03374956	COMPLETED	Obesity	Mayo Clinic	2017-12-11	PHASE3
NCT04986631	Recruiting	Obesity Childhood	University of Minnesota	2022-04-04	Early Phase 1
NCT01765218	TERMINATED	Hypoxic Ischemic Encephalopathy	Kristin R Hoffman	2013-02	PHASE1; PHASE2
NCT04095104	COMPLETED	Obesity, Morbid; Bariatric Surgery; Adolescent; Young Adult; Drug Therapy	University of Colorado, Denver	2020-01-15	PHASE2
NCT03018704	TERMINATED	Alcohol Use Disorder	VA Office of Research and Development	2017-08-01	PHASE4
NCT04453306	UNKNOWN	Obesity; Polycystic Ovary Syndrome; Hyperandrogenism	Hospital de Clinicas de Porto Alegre	2014-05	PHASE4
NCT04154813	UNKNOWN	Fluoxetine	Shanghai Mental Health Center	2020-02-01
NCT02878798	COMPLETED	Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome	Virginia Commonwealth University	2018-02-12	PHASE2
NCT03335163	COMPLETED	Migraine; Migraine;Menstrual; Contraception	University of Colorado, Denver	2018-03-15	PHASE1
NCT03479086	UNKNOWN	Alcohol Dependence	South West Sydney Local Health District	2017-06-20	PHASE3
NCT04401137	COMPLETED	Migraine	SK Chemicals Co., Ltd.	2020-07-01	PHASE1
NCT04523935	COMPLETED	Cerebral Palsy; Excessive Crying; Pain	Sathbhavana Brain Clinic	2005-12-07	PHASE4
NCT03828539	COMPLETED	Migraine	Novartis Pharmaceuticals	2019-02-22	PHASE4
NCT02635386	COMPLETED	Polycystic Ovary Syndrome; Obesity	Woman's	2016-03-22	PHASE3
NCT02201251	COMPLETED	Epilepsy	Janssen Research & Development, LLC	2014-10-06	PHASE3
NCT02371889	COMPLETED	Alcoholism; Alcohol Use Disorder (AUD)	University of Pennsylvania	2014-12-18	PHASE2
NCT02169830	TERMINATED	Migraine Disorders	St. Louis University	2014-08-22
NCT02239913	COMPLETED	Cocaine Use Disorder	University of Kentucky	2014-09	PHASE1
NCT01749215	COMPLETED	Alcohol Dependence; Posttraumatic Stress Disorder (PTSD)	University of California, San Francisco	2013-02	PHASE4
NCT03120468	COMPLETED	Alcoholism	Nassima Ait-Daoud Tiouririne	2017-05-01	EARLY_PHASE1
NCT03712917	COMPLETED	Migraine	Ataturk University	2019-03-01
NCT03767062	COMPLETED	Medication Overuse Headache; Chronic Migraine, Headache	Ataturk University	2019-03-01
NCT00182520	COMPLETED	Obsessive Compulsive Disorder	McMaster University	2002-01	PHASE4
NCT00182455	TERMINATED	Social Phobia	McMaster University	2004-03-01	PHASE4
NCT03354507	UNKNOWN	Epilepsy; Metabolic Acidosis; Tubular Acidosis; Renal	McMaster Children's Hospital	2018-01
NCT00606411	COMPLETED	Sleep-Related Eating Disorder	Massachusetts General Hospital	2008-01	EARLY_PHASE1
NCT02707965	COMPLETED	Epilepsy	Food and Drug Administration (FDA)	2017-06-08	PHASE1
NCT03280342	WITHDRAWN	Migraine; Headache	University of Minnesota	2017-10-30	PHASE2
NCT02301416	COMPLETED	Obesity; Metabolic Surgery; Weight Loss; Bariatric Surgery Procedures	Wake Forest University Health Sciences	2014-12	PHASE2
NCT02273804	COMPLETED	Obese Children and Adolescents	Assistance Publique - Hôpitaux de Paris	2016-06-01	PHASE3
NCT03308669	COMPLETED	Healthy	Eli Lilly and Company	2017-10-16	PHASE1
NCT01182766	COMPLETED	Alcohol Dependence; Nicotine Dependence	University of Virginia	2011-11-01	PHASE2; PHASE3
NCT03308669	Completed	Healthy	Eli Lilly and Company	2017-10-16	Phase 1
NCT02643719	WITHDRAWN	Migraine	NYU Langone Health	2015-12
NCT01426542	COMPLETED	Cyanotic Congenital Heart Disease	University of California, Davis	2011-03	PHASE1
NCT02645370	UNKNOWN	Migraine	Xijing Hospital	2016-02	PHASE1
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT01811940	COMPLETED	Cocaine Dependence	New York State Psychiatric Institute	2013-07	PHASE2; PHASE3
NCT02191579	COMPLETED	Migraine Disorders	Allergan	2014-08-05	PHASE4
NCT02074904	TERMINATED	Alcohol Drinking	University of Pennsylvania	2015-05	PHASE2
NCT02113787	COMPLETED	Epilepsy	Seoul National University Hospital	2014-02
NCT02553824	COMPLETED	Binge Eating Disorder; Bulimia Nervosa	Stanford University	2015-10-30	PHASE1
NCT01889602	COMPLETED	Cognitive Deficits	University of Minnesota	2013-07	PHASE4
NCT01789047	TERMINATED	Idiopathic Parkinson's Disease; Drug Induced Dyskinesia	Rush University Medical Center	2013-03	PHASE2
NCT02659475	COMPLETED	Binge Eating Disorder	Lindner Center of HOPE	2015-09	PHASE2
NCT00571246	WITHDRAWN	Alcohol Dependence; Post Traumatic Stress Disorder	Yale University	2012-06	PHASE3
NCT02138058	COMPLETED	Compulsive Shopping	University of Sao Paulo	2015-01	PHASE2
NCT01641445	COMPLETED	Alcohol Drinking	Brown University	2012-07	PHASE1; PHASE2
NCT01859013	COMPLETED	Obesity, Morbid; Obesity; Weight Loss	University of Minnesota	2013-06	PHASE2
NCT02810483	TERMINATED	Prader-Willi Syndrome	Assistance Publique - Hôpitaux de Paris	2012-12	PHASE3
NCT01750268	COMPLETED	Traumatic Brain Injury (TBI); Hazardous and Harmful Alcohol Use	University of California, San Francisco	2012-11	PHASE4
NCT00884884	COMPLETED	Alcohol Dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	2007-09	PHASE2; PHASE3
NCT01970566	WITHDRAWN	Obesity; Diabetes Mellitus	US Department of Veterans Affairs	2013-11
NCT01229735	COMPLETED	Epilepsy	UCB Korea Co., Ltd.	2010-11	PHASE4
NCT01581281	TERMINATED	Migraine; Migraine Disorders; Headache	Children's Hospital Medical Center, Cincinnati	2012-06	PHASE3
NCT02639598	COMPLETED	Chronic Migraine	Taipei Veterans General Hospital, Taiwan	2012-06	PHASE4
NCT00802412	COMPLETED	Nicotine Dependence; Alcohol Dependence	VA Office of Research and Development	2009-01	PHASE2
NCT01700387	COMPLETED	Chronic Migraine	Cady, Roger, M.D.	2012-10	PHASE4
NCT00572117	COMPLETED	Bipolar Disorder; Alcoholism; Alcohol Dependence	Stanford University	2007-08	PHASE4
NCT01161017	COMPLETED	Migraine	Rambam Health Care Campus	2008-07
NCT01834404	COMPLETED	Obesity	Mayo Clinic	2013-04	PHASE4
NCT01351753	TERMINATED	Obesity; Metabolic Syndrome X	University of Iowa	2011-03	PHASE2
NCT01764685	TERMINATED	Heavy Drinking; HIV; Alcohol Dependence	University of Pennsylvania	2013-01	PHASE2
NCT01241019	COMPLETED	Hypoxic Ischemic Encephalopathy	Meyer Children's Hospital IRCCS	2010-02	PHASE2
NCT00626925	COMPLETED	Alcohol Drinking	UConn Health	2008-02	PHASE4
NCT00862563	TERMINATED	Alcoholism; Alcohol Dependence; Alcohol Abuse	Boston Medical Center	2009-05	PHASE2
NCT01408641	TERMINATED	Alcohol Dependence; Alcoholism; Alcohol Abuse; Alcohol Use Disorder; PTSD; Posttraumatic Stress Disorder	University of Maryland, Baltimore	2012-09
NCT00448825	UNKNOWN	Alcohol Dependence; Cocaine Dependence	Bankole Johnson	2007-03	PHASE3
NCT00006205	UNKNOWN	Alcoholism	Bankole Johnson	2005-03	PHASE2
NCT00862095	TERMINATED	Headache	Madigan Army Medical Center	2008-06	PHASE4
NCT01087736	COMPLETED	PTSD; Alcohol Abuse; Alcoholism	University of California, San Francisco	2010-04	PHASE4
NCT01110434	COMPLETED	Cannabis Abuse; Cannabis Dependence	Brown University	2009-12	PHASE2
NCT01135602	UNKNOWN	Alcohol Dependence	Chiang Mai University	2010-07	PHASE4
NCT00393978	COMPLETED	Bipolar Disorder; Cannabis-Related Disorder	University of Cincinnati	2006-11	PHASE4
NCT01384279	COMPLETED	Obesity	Beitou Armed Forces Hospital, Taipei, Taiwan	2011-05
NCT00249691	UNKNOWN	Cocaine-Related Disorders	Bankole Johnson	2005-10	PHASE3
NCT01439438	COMPLETED	Epilepsy, Tonic-Clonic	GlaxoSmithKline	2011-07-22	PHASE1
NCT00732108	WITHDRAWN	Migraine; Headache; Dizziness	University of California, San Francisco	2008-11
NCT00685178	COMPLETED	Cocaine Dependence	Johns Hopkins University	2007-02	PHASE2
NCT00396734	SUSPENDED	Opioid-Related Disorders; Cocaine-Related Disorders	Hadassah Medical Organization	2007-04
NCT01145677	COMPLETED	Alcohol Dependence	Chiang Mai University	2010-06	PHASE2; PHASE3
NCT01627860	COMPLETED	Epilepsy	Johnson & Johnson Taiwan Ltd	2010-02	PHASE4
NCT00846495	COMPLETED	Migraine	Clinvest	2009-08	PHASE4
NCT01114854	COMPLETED	Epilepsy	Supernus Pharmaceuticals, Inc.	2010-06	PHASE1
NCT00777218	WITHDRAWN	Migraine	University of South Alabama	2007-08
NCT02884050	COMPLETED	Alteration of Cognitive Function	University of Florida	2009-04	PHASE1
NCT01843699	COMPLETED	Pathological Gambling	University of Sao Paulo	2009-06	PHASE2
NCT00769158	COMPLETED	Alcoholism	Bankole Johnson	2008-10	PHASE1
NCT00772031	COMPLETED	Chronic Migraine	Anne Lindblad	2008-10	PHASE3
NCT00753493	COMPLETED	Epilepsy; Migraines	University of Minnesota	2008-08	PHASE1
NCT01096420	COMPLETED	Patients With Chronic Migraine	Kuang Tien General Hospital	2008-08
NCT00988481	WITHDRAWN	Bulimia Nervosa	Neuropsychiatric Research Institute, Fargo, North Dakota	2009-09	PHASE4
NCT00794313	TERMINATED	Parkinson's Disease	Oregon Health and Science University	2009-09
NCT00550394	COMPLETED	Bipolar Disorder; Alcohol Abuse	University of Cincinnati	2008-04	PHASE4
NCT00421603	COMPLETED	Cocaine Dependence	New York State Psychiatric Institute	2007-02	PHASE2
NCT00563459	TERMINATED	Epilepsy; Seizures	SK Life Science, Inc.	2007-11	PHASE3
NCT00167245	COMPLETED	Alcoholism; Cocaine Dependence	Kyle Kampman	2004-09	PHASE2
NCT00223626	COMPLETED	Cocaine-Related Disorders	Bankole Johnson	2007-01	PHASE2
NCT01689649	COMPLETED	Epilepsy	Janssen Research & Development, LLC	2008-05-02	PHASE4
NCT02424318	COMPLETED	Migraine Disorders	SMG-SNU Boramae Medical Center	2008-12	PHASE4
NCT01799590	COMPLETED	Migraine	Janssen Pharmaceutical K.K.	2007-08	PHASE2
NCT00725920	COMPLETED	Posttraumatic Stress Disorder	Federal University of São Paulo	2007-01	PHASE4
NCT00812006	COMPLETED	Migraine	Organon and Co	2009-03-24	PHASE3
NCT00394095	COMPLETED	Bipolar Disorder; Weight Gain	University of Cincinnati	2006-12	PHASE4
NCT00855738	COMPLETED	Focal Epilepsy	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2007-05	PHASE4
NCT00463775	WITHDRAWN	Alcohol Dependence; Borderline Personality Disorder	Elizabeth Ralevski	2007-03	PHASE3
NCT00245583	TERMINATED	Pathological Gambling	Icahn School of Medicine at Mount Sinai	2005-10	PHASE3
NCT00554216	COMPLETED	Obesity	VIVUS LLC	2007-11	PHASE3
NCT00768209	COMPLETED	Hepatic Impairment	VIVUS LLC	2008-10	PHASE1
NCT00842400	COMPLETED	Obesity	VIVUS LLC	2009-02	PHASE1
NCT00768404	COMPLETED	Renal Impairment	VIVUS LLC	2008-10	PHASE1
NCT00598923	TERMINATED	Traumatic Brain Injury; Epilepsy	University of Pennsylvania	2004-11	EARLY_PHASE1
NCT01081795	COMPLETED	Migraine	Janssen Pharmaceutical K.K.	2007-04	PHASE2
NCT00206323	COMPLETED	Tourette Syndrome	Baylor College of Medicine	2004-09	PHASE3
NCT00206336	COMPLETED	Tourette Syndrome	Baylor College of Medicine	2004-10	PHASE3
NCT00755716	COMPLETED	Tobacco Dependence	UConn Health	2006-04	PHASE3
NCT00600067	COMPLETED	Diabetes	VIVUS LLC	2008-01	PHASE2
NCT00563368	COMPLETED	Obesity	VIVUS LLC	2007-12	PHASE3
NCT00345371	COMPLETED	Methamphetamine	National Institute on Drug Abuse (NIDA)	2006-04	PHASE2
NCT00154076	COMPLETED	Epilepsy	Eisai Korea Inc.	2005-09	PHASE4
NCT00223639	COMPLETED	Alcoholism	Bankole Johnson	2005-09	PHASE2
NCT00300742	COMPLETED	Alcohol Dependence; Binge Eating	University of Virginia	2006-03	PHASE2
NCT01060111	COMPLETED	Migraine	Janssen Korea, Ltd., Korea	2006-07	PHASE4
NCT00329407	COMPLETED	Alcoholism	Boston University	2003-09	PHASE4
NCT00518466	COMPLETED	Obesity	VIVUS LLC	2007-07	PHASE1
NCT00113815	COMPLETED	Partial Seizure Disorder; Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2005-05	PHASE3
NCT00286988	TERMINATED	Vomiting	Monarch Medical Research	2006-03	PHASE4
NCT00939692	COMPLETED	Healthy	Torrent Pharmaceuticals Limited	2007-01	PHASE1
NCT02283814	COMPLETED	Epilepsy	Bial - Portela C S.A.	2007-01	PHASE1
NCT00208858	COMPLETED	Tobacco Use Disorder	Emory University	2004-12	PHASE2
NCT00187928	COMPLETED	Obsessive-Compulsive Disorder	University of Florida	2003-01	PHASE3
NCT00065923	COMPLETED	Prader-Willi Syndrome; Self-Injurious Behavior	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	2002-07
NCT00648934	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2005-11	PHASE1
NCT00649467	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2005-11	PHASE1
NCT00649740	COMPLETED	Healthy	Mylan Pharmaceuticals Inc	2005-11	PHASE1
NCT00203463	COMPLETED	PTSD	Tuscaloosa Research & Education Advancement Corporation	2001-07	PHASE4
NCT00904943	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-06	PHASE1
NCT00905346	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-06	PHASE1
NCT00905164	COMPLETED	Healthy	Teva Pharmaceuticals USA	2002-06	PHASE1
NCT02040311	TERMINATED	Obesity	University of Copenhagen	2000-08	PHASE4
NCT00902473	COMPLETED	Healthy	Ranbaxy Laboratories Limited	2001-09
NCT00901784	COMPLETED	Healthy	Ranbaxy Laboratories Limited	2001-09
NCT00905567	COMPLETED	Healthy	Teva Pharmaceuticals USA	2001-06	PHASE1
NCT00905606	COMPLETED	Healthy	Teva Pharmaceuticals USA	2001-06	PHASE1
NCT00231608	COMPLETED	Obesity	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1998-12	PHASE2
NCT00231595	COMPLETED	Migraine; Common Migraine; Classic Migraine; Headache	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-03	PHASE3
NCT00237289	COMPLETED	Bipolar Disorder	Ortho-McNeil Neurologics, Inc.	2001-10	PHASE3
NCT00236873	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1989-10	PHASE2
NCT00752466	COMPLETED	Human Volunteers; Migraine	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2003-03	PHASE1
NCT00231634	TERMINATED	Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-05	PHASE3
NCT00266604	COMPLETED	Epilepsy; Seizures; Epilepsies, Partial; Epilepsy, Generalized; Seizures, Tonic-Clonic	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2005-12	PHASE4
NCT00237302	COMPLETED	Migraine	Ortho-McNeil Neurologics, Inc.	2001-07	PHASE3
NCT00307619	COMPLETED	Binge Eating	Janssen-Cilag Farmaceutica Ltda.	2003-11	PHASE3
NCT00212810	COMPLETED	Migraine; Headache; Classic Migraine; Common Migraine	Ortho-McNeil Neurologics, Inc.	2005-09	PHASE4
NCT00216606	COMPLETED	Migraine	Janssen Pharmaceutica N.V., Belgium	2003-12	PHASE3
NCT00216567	COMPLETED	Epilepsy, Rolandic	Janssen Korea, Ltd., Korea	2002-12	PHASE4
NCT00210496	COMPLETED	Migraine; Classic Migraine; Common Migraine	Janssen-Ortho LLC	2005-06	PHASE4
NCT00208130	COMPLETED	Post-Traumatic Stress Disorder	Creighton University	2001-10	PHASE4
NCT00236691	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1988-07	PHASE2
NCT00939705	COMPLETED	Healthy	Torrent Pharmaceuticals Limited		PHASE1
NCT00204386	COMPLETED	Posttraumatic Stress Disorder	University of Oklahoma	2002-09	PHASE2; PHASE3
NCT00210574	COMPLETED	Epilepsy, Absence	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2005-03	PHASE2
NCT00236626	COMPLETED	Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-04	PHASE2
NCT00231530	COMPLETED	Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-01	PHASE3
NCT00210821	COMPLETED	Migraine; Headache	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-02	PHASE3
NCT00231621	TERMINATED	Obesity; Hyperlipidemia; Hypertriglyceridemia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-05	PHASE3
NCT00236496	COMPLETED	Essential Tremor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-10	PHASE3
NCT00004807	COMPLETED	Rett Syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1995-01
NCT00236730	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1988-06	PHASE2
NCT00296959	TERMINATED	Parkinson's Disease	University Health Network, Toronto	2004-09	PHASE2
NCT00253175	COMPLETED	Vascular Headaches; Migraine	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-10	PHASE3
NCT00210808	COMPLETED	Obesity; Binge-Eating Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2003-09	PHASE2; PHASE3
NCT00200941	COMPLETED	Restless Legs Syndrome	Neurocare	2001-08	PHASE4
NCT00231647	COMPLETED	Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-02	PHASE2
NCT00768677	COMPLETED	Eating Disorders; Bulimia Nervosa	The Zucker Hillside Hospital	2003-07
NCT00035802	COMPLETED	Bipolar Disorder; Affective Disorders, Psychotic; Mood Disorders; Mental Disorders	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2002-01	PHASE3
NCT00131443	COMPLETED	Basilar Migraine	Monarch Medical Research	2004-02	PHASE2; PHASE3
NCT00236847	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1989-12	PHASE2
NCT00236613	COMPLETED	Obesity	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-09	PHASE2
NCT00210535	COMPLETED	Migraine; Vascular Headaches	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2005-06	PHASE3
NCT00243984	SUSPENDED	Metabolic Syndrome X; Diabetes Mellitus, Type 2	Northeastern Ohio Universities College of Medicine	2005-03	PHASE3
NCT00236860	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1989-05	PHASE2
NCT00280839	COMPLETED	Smoking Cessation	Lindner Center of HOPE		PHASE3
NCT00210925	COMPLETED	Alcoholism	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-03	PHASE2
NCT00233012	COMPLETED	Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2005-06	PHASE1
NCT00261469	COMPLETED	Headache	Janssen-Ortho Inc., Canada	2003-04	PHASE2
NCT00231673	COMPLETED	Diabetic Neuropathies; Diabetes Mellitus, Type 2; Polyneuropathies	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-07	PHASE2
NCT00236418	COMPLETED	Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1994-12	PHASE3
NCT00236717	COMPLETED	Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1997-09	PHASE3
NCT00236704	COMPLETED	Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1994-03	PHASE3
NCT00236561	COMPLETED	Migraine; Common Migraine; Classic Migraine; Headache	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-04	PHASE3
NCT00236639	COMPLETED	Obesity	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-07	PHASE3
NCT00011804	COMPLETED	Sciatica	National Institute of Dental and Craniofacial Research (NIDCR)	2001-02	PHASE2
NCT00432549	UNKNOWN	Analgesic Rebound Headache	The New England Center for Headache, P.C.	2007-01	PHASE4
NCT00236509	COMPLETED	Migraine; Common Migraine; Classic Migraine; Headache	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-02	PHASE3
NCT00231556	COMPLETED	Epilepsy; Seizures; Epilepsies, Partial; Epilepsy, Generalized; Epilepsy, Tonic-Clonic	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1999-07	PHASE3
NCT00370188	WITHDRAWN	Gambling	Centre for Addiction and Mental Health	2006-09	PHASE2
NCT00210860	COMPLETED	Migraine	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-09	PHASE3
NCT00240721	COMPLETED	Bipolar Disorders; Mood Disorders; Affective Disorders, Psychotic	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-10	PHASE3
NCT00153699	UNKNOWN	Glaucoma, Angle-Closure	Chinese University of Hong Kong	2004-09	PHASE4
NCT00210912	COMPLETED	Migraine	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2003-09	PHASE3
NCT00158002	COMPLETED	Basilar Migraine	Monarch Medical Research	2004-02	PHASE2
NCT00004776	COMPLETED	Lennox-Gastaut Syndrome	National Center for Research Resources (NCRR)	1993-11	PHASE3
NCT00236665	COMPLETED	Obesity; Hypertension	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-03	PHASE3
NCT00210782	COMPLETED	Epilepsy	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-06	PHASE3
NCT00236600	COMPLETED	Obesity	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-08	PHASE3
NCT00210873	COMPLETED	Migraine	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-02	PHASE3
NCT00211744	COMPLETED	Obsessive-compulsive Disorder	Montefiore Medical Center	2004-08	PHASE4
NCT00236886	COMPLETED	Epilepsy; Epilepsies, Partial; Epilepsy, Generalized; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1998-05	PHASE3
NCT00216619	COMPLETED	Migraine	Janssen Pharmaceutica N.V., Belgium	2003-11	PHASE3
NCT00701493	COMPLETED	Epilepsy	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2004-11	PHASE1
NCT00236756	COMPLETED	Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1993-08	PHASE3
NCT00986336	COMPLETED	Bipolar Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-02	PHASE1
NCT00266591	COMPLETED	Epilepsy; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1992-10	PHASE3
NCT00037674	COMPLETED	Bipolar Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-01	PHASE3
NCT00230698	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1995-11	PHASE3
NCT00236743	COMPLETED	Epilepsy; Epilepsies, Partial; Seizures	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	1994-06	PHASE3
NCT00203190	TERMINATED	Cluster Headache	Thomas Jefferson University	2004-09	PHASE4
NCT00035230	COMPLETED	Bipolar Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-07	PHASE3
NCT00231660	COMPLETED	Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2000-10	PHASE3
NCT00986128	COMPLETED	Bipolar Disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2001-03	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-17)

Check the Topiramate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Topiramate acts as a multi-targeted agent that inhibits voltage-gated sodium channels, blocks AMPA/kainate glutamate receptors, enhances GABA-A receptor activity, and inhibits carbonic anhydrase isozymes II and IV. By suppressing excessive neuronal hyperexcitability and modulating metabolic pathways, this compound exerts potent anticonvulsant and neuroprotective effects relevant to clinical trials evaluating epilepsy, migraine prophylaxis, and metabolic conditions such as obesity.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).